Feedback / Questions
CSTI-500 - ConSynance
https://www.globenewswire.com/news-release/2024/07/24/2918161/0/en/ConSynance-Therapeutics-Announces-U-S-FDA-Grants-Rare-Pediatric-Disease-Designation-to-CSTI-500-a-Potential-First-in-Class-Therapy-for-Prader-Willi-Syndrome.html
Jul 24, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next